Copyright Reports & Markets. All rights reserved.

Global Chronic Obstructive Pulmonary Disorder (COPD) Market Research Report 2019

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Key Market Segments
  • 1.3 Players Covered: Ranking by Chronic Obstructive Pulmonary Disorder (COPD) Revenue
  • 1.4 Market by Type
    • 1.4.1 Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size Growth Rate by Type: 2020 VS 2026
    • 1.4.2 Short-Acting Bronchodilators
    • 1.4.3 Corticosteroids
    • 1.4.4 Methylxanthines
    • 1.4.5 Long-Acting Bronchodilators
    • 1.4.6 Phosphodiesterase-4 Inhibitors
    • 1.4.7 Others
  • 1.5 Market by Application
    • 1.5.1 Global Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Application: 2020 VS 2026
    • 1.5.2 Hospital
    • 1.5.3 Clinic
  • 1.6 Study Objectives
  • 1.7 Years Considered

2 Global Growth Trends

  • 2.1 Global Chronic Obstructive Pulmonary Disorder (COPD) Market Perspective (2015-2026)
  • 2.2 Global Chronic Obstructive Pulmonary Disorder (COPD) Growth Trends by Regions
    • 2.2.1 Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Regions: 2015 VS 2020 VS 2026
    • 2.2.2 Chronic Obstructive Pulmonary Disorder (COPD) Historic Market Share by Regions (2015-2020)
    • 2.2.3 Chronic Obstructive Pulmonary Disorder (COPD) Forecasted Market Size by Regions (2021-2026)
  • 2.3 Industry Trends and Growth Strategy
    • 2.3.1 Market Top Trends
    • 2.3.2 Market Drivers
    • 2.3.3 Market Challenges
    • 2.3.4 Porter’s Five Forces Analysis
    • 2.3.5 Chronic Obstructive Pulmonary Disorder (COPD) Market Growth Strategy
    • 2.3.6 Primary Interviews with Key Chronic Obstructive Pulmonary Disorder (COPD) Players (Opinion Leaders)

3 Competition Landscape by Key Players

  • 3.1 Global Top Chronic Obstructive Pulmonary Disorder (COPD) Players by Market Size
    • 3.1.1 Global Top Chronic Obstructive Pulmonary Disorder (COPD) Players by Revenue (2015-2020)
    • 3.1.2 Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue Market Share by Players (2015-2020)
    • 3.1.3 Global Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.2 Global Chronic Obstructive Pulmonary Disorder (COPD) Market Concentration Ratio
    • 3.2.1 Global Chronic Obstructive Pulmonary Disorder (COPD) Market Concentration Ratio (CR5 and HHI)
    • 3.2.2 Global Top 10 and Top 5 Companies by Chronic Obstructive Pulmonary Disorder (COPD) Revenue in 2019
  • 3.3 Chronic Obstructive Pulmonary Disorder (COPD) Key Players Head office and Area Served
  • 3.4 Key Players Chronic Obstructive Pulmonary Disorder (COPD) Product Solution and Service
  • 3.5 Date of Enter into Chronic Obstructive Pulmonary Disorder (COPD) Market
  • 3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)

  • 4.1 Global Chronic Obstructive Pulmonary Disorder (COPD) Historic Market Size by Type (2015-2020)
  • 4.2 Global Chronic Obstructive Pulmonary Disorder (COPD) Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)

  • 5.1 Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Application (2015-2020)
  • 5.2 Global Chronic Obstructive Pulmonary Disorder (COPD) Forecasted Market Size by Application (2021-2026)

6 North America

  • 6.1 North America Chronic Obstructive Pulmonary Disorder (COPD) Market Size (2015-2020)
  • 6.2 Chronic Obstructive Pulmonary Disorder (COPD) Key Players in North America (2019-2020)
  • 6.3 North America Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Type (2015-2020)
  • 6.4 North America Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Application (2015-2020)

7 Europe

  • 7.1 Europe Chronic Obstructive Pulmonary Disorder (COPD) Market Size (2015-2020)
  • 7.2 Chronic Obstructive Pulmonary Disorder (COPD) Key Players in Europe (2019-2020)
  • 7.3 Europe Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Type (2015-2020)
  • 7.4 Europe Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Application (2015-2020)

8 China

  • 8.1 China Chronic Obstructive Pulmonary Disorder (COPD) Market Size (2015-2020)
  • 8.2 Chronic Obstructive Pulmonary Disorder (COPD) Key Players in China (2019-2020)
  • 8.3 China Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Type (2015-2020)
  • 8.4 China Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Application (2015-2020)

9 Japan

  • 9.1 Japan Chronic Obstructive Pulmonary Disorder (COPD) Market Size (2015-2020)
  • 9.2 Chronic Obstructive Pulmonary Disorder (COPD) Key Players in Japan (2019-2020)
  • 9.3 Japan Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Type (2015-2020)
  • 9.4 Japan Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Application (2015-2020)

10 Southeast Asia

  • 10.1 Southeast Asia Chronic Obstructive Pulmonary Disorder (COPD) Market Size (2015-2020)
  • 10.2 Chronic Obstructive Pulmonary Disorder (COPD) Key Players in Southeast Asia (2019-2020)
  • 10.3 Southeast Asia Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Type (2015-2020)
  • 10.4 Southeast Asia Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Application (2015-2020)

11 India

  • 11.1 India Chronic Obstructive Pulmonary Disorder (COPD) Market Size (2015-2020)
  • 11.2 Chronic Obstructive Pulmonary Disorder (COPD) Key Players in India (2019-2020)
  • 11.3 India Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Type (2015-2020)
  • 11.4 India Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Application (2015-2020)

12 Central & South America

  • 12.1 Central & South America Chronic Obstructive Pulmonary Disorder (COPD) Market Size (2015-2020)
  • 12.2 Chronic Obstructive Pulmonary Disorder (COPD) Key Players in Central & South America (2019-2020)
  • 12.3 Central & South America Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Type (2015-2020)
  • 12.4 Central & South America Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Application (2015-2020)

13 Key Players Profiles

  • 13.1 GSK
    • 13.1.1 GSK Company Details
    • 13.1.2 GSK Business Overview
    • 13.1.3 GSK Chronic Obstructive Pulmonary Disorder (COPD) Introduction
    • 13.1.4 GSK Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2015-2020))
    • 13.1.5 GSK Recent Development
  • 13.2 Pfizer
    • 13.2.1 Pfizer Company Details
    • 13.2.2 Pfizer Business Overview
    • 13.2.3 Pfizer Chronic Obstructive Pulmonary Disorder (COPD) Introduction
    • 13.2.4 Pfizer Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2015-2020)
    • 13.2.5 Pfizer Recent Development
  • 13.3 Merck
    • 13.3.1 Merck Company Details
    • 13.3.2 Merck Business Overview
    • 13.3.3 Merck Chronic Obstructive Pulmonary Disorder (COPD) Introduction
    • 13.3.4 Merck Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2015-2020)
    • 13.3.5 Merck Recent Development
  • 13.4 Novartis
    • 13.4.1 Novartis Company Details
    • 13.4.2 Novartis Business Overview
    • 13.4.3 Novartis Chronic Obstructive Pulmonary Disorder (COPD) Introduction
    • 13.4.4 Novartis Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2015-2020)
    • 13.4.5 Novartis Recent Development
  • 13.5 AstraZeneca
    • 13.5.1 AstraZeneca Company Details
    • 13.5.2 AstraZeneca Business Overview
    • 13.5.3 AstraZeneca Chronic Obstructive Pulmonary Disorder (COPD) Introduction
    • 13.5.4 AstraZeneca Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2015-2020)
    • 13.5.5 AstraZeneca Recent Development
  • 13.6 Boehringer Ingelheim
    • 13.6.1 Boehringer Ingelheim Company Details
    • 13.6.2 Boehringer Ingelheim Business Overview
    • 13.6.3 Boehringer Ingelheim Chronic Obstructive Pulmonary Disorder (COPD) Introduction
    • 13.6.4 Boehringer Ingelheim Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2015-2020)
    • 13.6.5 Boehringer Ingelheim Recent Development
  • 13.7 Teva Pharmaceuticals
    • 13.7.1 Teva Pharmaceuticals Company Details
    • 13.7.2 Teva Pharmaceuticals Business Overview
    • 13.7.3 Teva Pharmaceuticals Chronic Obstructive Pulmonary Disorder (COPD) Introduction
    • 13.7.4 Teva Pharmaceuticals Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2015-2020)
    • 13.7.5 Teva Pharmaceuticals Recent Development
  • 13.8 Ario Pharma
    • 13.8.1 Ario Pharma Company Details
    • 13.8.2 Ario Pharma Business Overview
    • 13.8.3 Ario Pharma Chronic Obstructive Pulmonary Disorder (COPD) Introduction
    • 13.8.4 Ario Pharma Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2015-2020)
    • 13.8.5 Ario Pharma Recent Development
  • 13.9 Roche
    • 13.9.1 Roche Company Details
    • 13.9.2 Roche Business Overview
    • 13.9.3 Roche Chronic Obstructive Pulmonary Disorder (COPD) Introduction
    • 13.9.4 Roche Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2015-2020)
    • 13.9.5 Roche Recent Development
  • 13.10 Ache
    • 13.10.1 Ache Company Details
    • 13.10.2 Ache Business Overview
    • 13.10.3 Ache Chronic Obstructive Pulmonary Disorder (COPD) Introduction
    • 13.10.4 Ache Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2015-2020)
    • 13.10.5 Ache Recent Development
  • 13.11 Almirall
    • 10.11.1 Almirall Company Details
    • 10.11.2 Almirall Business Overview
    • 10.11.3 Almirall Chronic Obstructive Pulmonary Disorder (COPD) Introduction
    • 10.11.4 Almirall Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2015-2020)
    • 10.11.5 Almirall Recent Development
  • 13.12 Aquinox Pharmaceuticals
    • 10.12.1 Aquinox Pharmaceuticals Company Details
    • 10.12.2 Aquinox Pharmaceuticals Business Overview
    • 10.12.3 Aquinox Pharmaceuticals Chronic Obstructive Pulmonary Disorder (COPD) Introduction
    • 10.12.4 Aquinox Pharmaceuticals Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2015-2020)
    • 10.12.5 Aquinox Pharmaceuticals Recent Development
  • 13.13 Asmacure
    • 10.13.1 Asmacure Company Details
    • 10.13.2 Asmacure Business Overview
    • 10.13.3 Asmacure Chronic Obstructive Pulmonary Disorder (COPD) Introduction
    • 10.13.4 Asmacure Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2015-2020)
    • 10.13.5 Asmacure Recent Development
  • 13.14 Astellas Pharma
    • 10.14.1 Astellas Pharma Company Details
    • 10.14.2 Astellas Pharma Business Overview
    • 10.14.3 Astellas Pharma Chronic Obstructive Pulmonary Disorder (COPD) Introduction
    • 10.14.4 Astellas Pharma Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2015-2020)
    • 10.14.5 Astellas Pharma Recent Development

14 Analyst's Viewpoints/Conclusions

    15 Appendix

    • 15.1 Research Methodology
      • 15.1.1 Methodology/Research Approach
      • 15.1.2 Data Source
    • 15.2 Disclaimer

    Chronic Obstructive Pulmonary Disorder (COPD) market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Chronic Obstructive Pulmonary Disorder (COPD) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

    The key players covered in this study
    GSK
    Pfizer
    Merck
    Novartis
    AstraZeneca
    Boehringer Ingelheim
    Teva Pharmaceuticals
    Ario Pharma
    Roche
    Ache
    Almirall
    Aquinox Pharmaceuticals
    Asmacure
    Astellas Pharma

    Market segment by Type, the product can be split into
    Short-Acting Bronchodilators
    Corticosteroids
    Methylxanthines
    Long-Acting Bronchodilators
    Phosphodiesterase-4 Inhibitors
    Others
    Market segment by Application, split into
    Hospital
    Clinic

    Market segment by Regions/Countries, this report covers
    North America
    Europe
    China
    Japan
    Southeast Asia
    India
    Central & South America

    Buy now